Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Recent Study Shows Leukotheraâ„¢ Combined with Other Agents Has Enhanced Anti-Leukemia Effects

June 27, 2011 By Bio-Medicine.Org

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ — Recent
findings published in the scientific journal Leukemia
Research
(
http://www.sciencedirect.com/science/article/pii/S0145212611002505),
showed that when combined with standard anti-leukemia agents, the
biological activity of LeukotheraTM, a drug candidate
under development by Actinobac Biomed, Inc., showed synergistic
anti-leukemia effects.

The outcome of these in vitro experiments
demonstrated that combining LeukotheraTM with
such widely employed drugs as etoposide, mitoxantrone,
daunorubicin, busulfan and imatinib killed leukemia cells much more
effectively than when the agents were used alone.
 LeukotheraTM is a natural biologic agent that
specifically targets malignant and/or inflammatory white blood
cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained.
“Drug combination therapies for cancer are now frequently
considered by oncologists due to their many advantages, which
include the possibility of reducing doses of toxic chemotherapeutic
agents and a lower chance of developing drug resistance,” he said.
 “The biological mechanism of LeukotheraTM differs
from that of other cancer drugs so including it to blood cancer
treatment protocols may be a highly effective strategy.”

Actinobac Biomed, Inc. was founded in 2009 with financial
backing from Foundation Venture Capital Group, LLC, to develop
commercial products based upon technology developed at the
University of Medicine and Dentistry of New Jersey.  The
company has exclusively licensed the rights to develop
LeukotheraTM as a therapeutic agent for the treatment of
hematologic malignancies, autoimmune and inflammatory diseases and
HIV infection.

“We provided early seed funding to Actinobac because we are
convinced that

‘/>”/>

SOURCE

Related Articles Read More >

Verily Study Watch
Verily says its Study Watch could identify heart failure risk
A child using a medical device at home.
Device design takes the spotlight among 2024’s top health tech hazards
These 11 medical device inventions are the best of 2023, Time magazine says
A photo of a Best Buy Geek Squad employee helping a chronic care patient with a remote monitoring device.
Device manufacturers have an unexpected ally for at-home health care
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe